Title:
ALK ANTIBODIES, CONJUGATES, AND CHIMERIC ANTIGEN RECEPTORS, AND THEIR USE
Document Type and Number:
WIPO Patent Application WO/2015/069922
Kind Code:
A3
Abstract:
Chimeric antigen receptors that specifically bind to anaplastic lymphoma kinase are disclosed. Nucleic acids, recombinant expression vectors, host cells, antibodies, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
Inventors:
ORENTAS RIMAS (US)
MACKALL CRYSTAL (US)
MACKALL CRYSTAL (US)
Application Number:
PCT/US2014/064383
Publication Date:
September 03, 2015
Filing Date:
November 06, 2014
Export Citation:
Assignee:
US HEALTH (US)
International Classes:
C07K14/725; C07K16/30; C07K16/46
Other References:
ORENTAS, RJ ET AL.: "Designing a New Chimeric Antigen Receptor for the TumorAntigen ALK", vol. 33, no. 8, 1 October 2010 (2010-10-01), pages 905 - 905, XP055169988, Retrieved from the Internet [retrieved on 20150216]
RIMAS J ORENTAS ET AL: "ALK (anaplastic lymphoma kinase, CD246)-specific CARs: new immunotherapeutic agents for the treatment of pediatric solid tumors", JOURNAL FOR IMMUNOTHERAPY OF CANCER, BIOMED CENTRAL LTD, LONDON, UK, vol. 1, no. Suppl 1, 7 November 2013 (2013-11-07), pages P27, XP021167231, ISSN: 2051-1426, DOI: 10.1186/2051-1426-1-S1-P27
RIMAS J. ORENTAS ET AL: "Immunotherapy Targets in Pediatric Cancer", FRONTIERS IN ONCOLOGY, vol. 2, 1 January 2012 (2012-01-01), XP055170174, DOI: 10.3389/fonc.2012.00003
RIMAS J. ORENTAS ET AL: "Identification of Cell Surface Proteins as Potential Immunotherapy Targets in 12 Pediatric Cancers", FRONTIERS IN ONCOLOGY, vol. 2, 1 January 2012 (2012-01-01), XP055127272, DOI: 10.3389/fonc.2012.00194
YAËL P. MOSSÉ ET AL: "Identification of ALK as a major familial neuroblastoma predisposition gene", NATURE, vol. 455, no. 7215, 16 October 2008 (2008-10-16), pages 930 - 935, XP055004093, ISSN: 0028-0836, DOI: 10.1038/nature07261
MAZOT PIERRE ET AL: "Internalization and Down-Regulation of the ALK Receptor in Neuroblastoma Cell Lines upon Monoclonal Antibodies Treatment", PLOS ONE, vol. 7, no. 3, March 2012 (2012-03-01), XP002736064
LEE D W ET AL: "The Future Is Now: Chimeric Antigen Receptors as New Targeted Therapies for Childhood Cancer", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 18, no. 10, 15 May 2012 (2012-05-15), pages 2780 - 2790, XP002725492, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-11-1920
MOOG-LUTZ CHRISTEL ET AL: "Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 280, no. 28, 1 July 2005 (2005-07-01), pages 26039 - 26048, XP002424604, ISSN: 0021-9258, DOI: 10.1074/JBC.M501972200
ALEC WALKER ET AL: "Targeting high-risk pediatric solid tumors with CAR T cells directed against ALK (anaplastic lymphoma kinase, CD246)", JOURNAL FOR IMMUNOTHERAPY OF CANCER, BIOMED CENTRAL LTD, LONDON, UK, vol. 2, no. Suppl 3, 6 November 2014 (2014-11-06), pages P40, XP021202601, ISSN: 2051-1426, DOI: 10.1186/2051-1426-2-S3-P40
RIMAS J ORENTAS ET AL: "ALK (anaplastic lymphoma kinase, CD246)-specific CARs: new immunotherapeutic agents for the treatment of pediatric solid tumors", JOURNAL FOR IMMUNOTHERAPY OF CANCER, BIOMED CENTRAL LTD, LONDON, UK, vol. 1, no. Suppl 1, 7 November 2013 (2013-11-07), pages P27, XP021167231, ISSN: 2051-1426, DOI: 10.1186/2051-1426-1-S1-P27
RIMAS J. ORENTAS ET AL: "Immunotherapy Targets in Pediatric Cancer", FRONTIERS IN ONCOLOGY, vol. 2, 1 January 2012 (2012-01-01), XP055170174, DOI: 10.3389/fonc.2012.00003
RIMAS J. ORENTAS ET AL: "Identification of Cell Surface Proteins as Potential Immunotherapy Targets in 12 Pediatric Cancers", FRONTIERS IN ONCOLOGY, vol. 2, 1 January 2012 (2012-01-01), XP055127272, DOI: 10.3389/fonc.2012.00194
YAËL P. MOSSÉ ET AL: "Identification of ALK as a major familial neuroblastoma predisposition gene", NATURE, vol. 455, no. 7215, 16 October 2008 (2008-10-16), pages 930 - 935, XP055004093, ISSN: 0028-0836, DOI: 10.1038/nature07261
MAZOT PIERRE ET AL: "Internalization and Down-Regulation of the ALK Receptor in Neuroblastoma Cell Lines upon Monoclonal Antibodies Treatment", PLOS ONE, vol. 7, no. 3, March 2012 (2012-03-01), XP002736064
LEE D W ET AL: "The Future Is Now: Chimeric Antigen Receptors as New Targeted Therapies for Childhood Cancer", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 18, no. 10, 15 May 2012 (2012-05-15), pages 2780 - 2790, XP002725492, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-11-1920
MOOG-LUTZ CHRISTEL ET AL: "Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 280, no. 28, 1 July 2005 (2005-07-01), pages 26039 - 26048, XP002424604, ISSN: 0021-9258, DOI: 10.1074/JBC.M501972200
ALEC WALKER ET AL: "Targeting high-risk pediatric solid tumors with CAR T cells directed against ALK (anaplastic lymphoma kinase, CD246)", JOURNAL FOR IMMUNOTHERAPY OF CANCER, BIOMED CENTRAL LTD, LONDON, UK, vol. 2, no. Suppl 3, 6 November 2014 (2014-11-06), pages P40, XP021202601, ISSN: 2051-1426, DOI: 10.1186/2051-1426-2-S3-P40
Attorney, Agent or Firm:
SCOTT, Gregory, K. (LLPOne World Trade Center, Suite 1600,121 SW Salmon Stree, Portland OR, US)
Download PDF:
Previous Patent: STORAGE ARRAY PASSWORD MANAGEMENT
Next Patent: IMPROVED MEASUREMENT OF DOWNHOLE GAMMA RADIATION BY REDUCTION OF COMPTON SCATTERING
Next Patent: IMPROVED MEASUREMENT OF DOWNHOLE GAMMA RADIATION BY REDUCTION OF COMPTON SCATTERING